ライフサイエンスコーパス: vascular disease

1 cular disease, heart failure, and peripheral vascular disease).

2 coronary heart disease and death due to the vascular diseases).

3 or an anti-inflammatory approach in diabetic vascular disease.

4 elopment of TAAD and proliferative occlusive vascular disease.

5 fferentiation and negatively correlated with vascular disease.

6 ve the potential to mediate cytotoxicity and vascular disease.

7 ular pathological changes and development of vascular disease.

8 nd 29.8 (21.7-40.8) for diabetes followed by vascular disease.

9 erating room for young children with retinal vascular disease.

10 es, types, and consequences of DNA damage in vascular disease.

11 hronic pulmonary insufficiency; and cerebral vascular disease.

12 ricular stiffness, and concomitant pulmonary vascular disease.

13 y CCN3 as a potential therapeutic target for vascular disease.

14 nal procedures used for treating obstructive vascular disease.

15 rtant atheroprotective potential in diabetic vascular disease.

16 contribute to unique phenotypes in pulmonary vascular disease.

17 a major contribution to VSMC accumulation in vascular disease.

18 ular death was applied to 6904 patients with vascular disease.

19 potential therapeutic application in ocular vascular disease.

20 ents with T2DM and prevalent atherosclerotic vascular disease.

21 r mechanisms, many of which are activated in vascular disease.

22 enotype may contribute to the development of vascular disease.

23 ay contribute to endothelial dysfunction and vascular disease.

24 choices for the management of patients with vascular disease.

25 ll senescence, and apoptosis, are present in vascular disease.

26 evels of Abeta in plasma are associated with vascular disease.

27 14671 patients with T2DM and atherosclerotic vascular disease.

28 ntribute to different VSMC behavior and thus vascular disease.

29 ons for angiogenesis, tissue engineering and vascular disease.

30 mitochondrial dysfunction may contribute to vascular disease.

31 ft failure censored for death was peripheral vascular disease.

32 gnalling as potential therapeutic targets in vascular disease.

33 egy for therapeutic transdifferentiation for vascular disease.

34 osis of the BD type of subcortical ischaemic vascular disease.

35 ension and thus underlies the development of vascular disease.

36 ties on the incidence of particular types of vascular disease.

37 s) comprise an uncommon but life-threatening vascular disease.

38 s elafin-mediated reversibility of pulmonary vascular disease.

39 ntribute to age-related pathologies, such as vascular disease.

40 roke, venous thromboembolism, and peripheral vascular disease.

41 rrest, chronic heart disease, and peripheral vascular disease.

42 athways may prove useful in the treatment of vascular disease.

43 oagulant systems, contributing to thrombotic vascular disease.

44 m by which BMPR2 mutations promote pulmonary vascular disease.

45 ism (PE) is a serious and prevalent cause of vascular disease.

46 ment of diabetic bone marrow mobilopathy and vascular disease.

47 mal amino acid metabolism is associated with vascular disease.

48 gest that TSPAN2 may play important roles in vascular disease.

49 fibrous cap stability with implications for vascular disease.

50 asive hemodynamics consistent with pulmonary vascular disease.

51 ease but lower odds of small-vessel cerebral vascular disease.

52 ation, progression and clinical treatment of vascular disease.

53 variety of inflammatory conditions including vascular disease.

54 macrophages as a therapy for atherosclerotic vascular disease.

55 novel therapeutic target for atherosclerotic vascular disease.

56 ource OCTA (MIOCTA) in children with retinal vascular disease.

57 l cells, this phenomenon might contribute to vascular disease.

58 ificant implications for the pathogenesis of vascular diseases.

59 g therapeutic strategy for treatment of many vascular diseases.

60 to TNFalpha-induced inflammation in retinal vascular diseases.

61 in a variety of both inherited and acquired vascular diseases.

62 ing fundamental pathophysiology in pulmonary vascular diseases.

63 ammation in a target organ (eg, the skin) on vascular diseases.

64 thogenesis and clinical prognosis of retinal vascular diseases.

65 systemic inflammation encountered in common vascular diseases.

66 oring disease progression in several retinal vascular diseases.

67 l strategy for the treatment of inflammatory vascular diseases.

68 ndation for cystoid macular edema in retinal vascular diseases.

69 cs of hard exudates in patients with retinal vascular diseases.

70 w cell-free vascular grafts for treatment of vascular diseases.

71 ns may develop in a wide spectrum of retinal vascular diseases.

72 s; few have examined associations with other vascular diseases.

73 and function of PDEs in SMC pathogenesis of vascular diseases.

74 essels, especially those directly related to vascular diseases.

75 oth vascular developmental biology and adult vascular diseases.

76 r factor contributing to the pathogenesis of vascular diseases.

77 umab, rescue vision in patients with retinal vascular diseases.

78 y role in the pathogenesis of a multitude of vascular diseases.

79 d contribute to the pathogenesis of multiple vascular diseases.

80 e acutely lethal manifestations of heart and vascular diseases.

81 in microvascular dysfunction in CAD or other vascular diseases.

82 red blood cells has been implicated in many vascular diseases.

83 rt disease, stroke, heart failure, and other vascular diseases.

84 rtension, stroke, myocardial infarction, and vascular diseases.

85 sms, acute aortic dissections, and occlusive vascular diseases.

86 a therapeutic approach in TGF-beta-dependent vascular diseases.

87 abetes (0.62, 0.43-0.90; p=0.01), peripheral vascular disease (0.27, 0.17-0.45; p<0.0001), hyperchole

88 rose: heart failure (13.9%-34.4%), pulmonary vascular disease (1.2%-7.1%), valvular heart disease (5.

89 7%), esophagus variceal hemorrhage (3%), and vascular diseases (10%).

90 ents With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the Amer

91 y function (31% vs. 24%), and had peripheral vascular disease (21% vs. 11%) more often than patients

92 ons (12.8%), bleeding (7.6%), and peripheral vascular disease (4.3%) were the most common noncardiac

93 prior transient ischemic attack, peripheral vascular disease, absence of prior coronary artery bypas

94 leeper were higher among men with peripheral vascular disease (adjusted odds ratio (aOR) = 6.54, 95%

95 etes, ischaemic heart disease and peripheral vascular disease (adjusted OR=1.4, 2.0, 1.9 and 2.2, res

96 cs have led to a deeper understanding of how vascular disease affects cognition.

97 rotection against TGF-beta-induced pulmonary vascular disease after Schistosoma exposure, and targete

98 revious stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) score is r

99 revious stroke or transient ischemic attack, vascular disease, age 65 to 74 years, female) score of >

100 mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category) scor

101 mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category) scor

102 age >/=75 years, diabetes, previous stroke, vascular disease, age 65 to 74, and female sex) score mi

103 , prior stroke or transient ischemic attack, vascular disease, age 65 to 74, female (CHA2DS2-VASc) sc

104 oubled], diabetes mellitus, stroke [doubled]-vascular disease, age 65-74 years, and sex category [fem

105 abetes mellitus, prior stroke/TIA (doubled), vascular disease, age 65-74 years, sex category (female)

106 years [doubled], diabetes, stroke [doubled], vascular disease, age 65-74 years, sex category [female]

107 mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category) are con

108 , prior stroke or transient ischemic attack, vascular disease, age 65-74, and sex category [female])

109 , previous stroke/transient ischemic attack, vascular disease, aged 65 to 74 years, and female sex) i

110 Microangiopathy and vascular disease also contribute to the neuropathology i

111 roach may also reduce the increased risk for vascular diseases among migraineurs.

112 ous thromboembolism (VTE), which is a common vascular disease and a major cause of morbidity and mort

113 Thus, pleiotropic functions of TWIST control vascular disease and development.

114 Vascular disease and heart failure impart an enormous bu

115 te and with a lower prevalence of peripheral vascular disease and history of prior cardiac surgeries.

116 Peripheral vascular disease and IADL impairment, but not chronologi

117 nt of the diagnosis of cardiac and pulmonary vascular disease and interventions aimed at managing the

118 LA function is associated with pulmonary vascular disease and right HF in both HF phenotypes, but

119 pathway activation has a profound effect on vascular disease and support the conclusion that inflamm

120 and von Willebrand factor, may contribute to vascular disease and thrombosis.

121 x reaction, protein methionine oxidation, in vascular disease and thrombosis.

122 r patients with DME who are at high risk for vascular disease and were not included in these trials.

123 en linked to reduced mortality from specific vascular diseases and cancers.

124 lations during the natural course of retinal vascular diseases and following treatment is warranted.

125 , hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases.

126 rebral infarction, heart failure, peripheral vascular disease, and cardiac arrhythmia) and neuropsych

127 eter [PA:A] ratio >1), a marker of pulmonary vascular disease, and exacerbations.

128 re-operative intravenous inotropes, arterial vascular disease, and higher degree of calcifications.

129 he broad areas of CHD-related heart failure, vascular disease, and multisystem complications.

130 abetes in overweight and obese patients with vascular disease, and pay increased attention to prevent

131 schemic attack or thromboembolism [2 points]-vascular disease, and sex category [female]) risk score

132 miRNAs as therapeutic targets in cardiac and vascular disease, and their use as novel biomarkers.

133 ation duration, race, vascular risk factors, vascular diseases, and apolipoprotein epsilon4 level.

134 s suffering from many different inflammatory vascular diseases, and their formation in animal models

135 pathways in angiogenesis relevant to cancer, vascular diseases, and wound healing.

136 plicated in a range of neurodegenerative and vascular diseases, and yet the underlying molecular mech

137 dementia; chronic kidney disease; peripheral vascular disease; and, among patients aged 65 years or o

138 sion, chronic kidney disease, and peripheral vascular disease; and, among those aged 66 years or olde

139 On multivariate analysis, prior bleeds, vascular disease, anemia, prior stroke, and liver dysfun

140 (BPD), but whether early signs of pulmonary vascular disease are associated with the subsequent deve

141 Both forms of vascular disease are driven by diverse risk factors, wit

142 Collateral pathways in vascular disease are important natural "bypass" conduits

143 Retinal vascular diseases are among the leading causes of acquir

144 Retinal vascular diseases are important causes of vision loss.

145 lar inflammation and associated inflammatory vascular diseases are not well defined.

146 the clinical diagnosis of cardiac and brain vascular diseases as discernible from the enormous amoun

147 SFA consumption and risk of atherosclerotic vascular disease (ASVD) mortality.

148 ranslates to a lower risk of atherosclerotic vascular disease (ASVD) mortality.The objective was to i

149 ns of LDL-C >/=190 mg/dL without preexisting vascular disease at baseline.

150 after excluding individuals with evidence of vascular disease at baseline.

151 ry setting, including medical strategies for vascular disease, atrial fibrillation, and heart failure

152 Mutation carriers may be predisposed to vascular diseases because of weakened vessel walls under

153 w in Fontan circulation results in pulmonary vascular disease, but the potential relationships betwee

154 ological conditions, including inflammation, vascular diseases, cancer mortality, and high risk for h

155 Abdominal aortic aneurysm is a dynamic vascular disease characterized by inflammatory cell inva

156 , previous stroke/transient ischemic attack, vascular diseases, chronic kidney disease and chronic ob

157 Diabetes increases the risk of Cardio-vascular disease (CVD).

158 Asian countries largely surrounds stroke and vascular disease, dementia and lifestyle factors that ar

159 ory and stimulatory effects in the course of vascular disease development.

160 ights into the inflammatory process by which vascular disease develops.

161 isease, cerebrovascular accident, peripheral vascular disease, diabetes mellitus, liver disease, lung

162 Because the extent of vascular disease differs substantially between men and w

163 ystolic and diastolic dysfunction, pulmonary vascular disease, endothelial dysfunction, and periphera

164 Peripheral vascular disease existed in 308 KT candidates at waitlis

165 Among those with vascular disease, factors capable of influencing arteria

166 eart disease or stroke), 12.0 (8.1-17.9) for vascular disease followed by diabetes, 18.6 (16.6-20.9)

167 Of 47 611 patients with stable vascular disease followed for 3 years in both studies th

168 436 patients with various manifestations of vascular disease from the TNT (Treating to New Targets),

169 Persons with collagen vascular disease had 35% lower odds of KCN (adjusted OR,

170 sing computerized tomography, PLWHIV without vascular disease had higher rates of any carotid plaque

171 ; 95% CI, 1.15 to 6.36), whereas preexisting vascular disease had no association with HF ( P > .05).

172 lammation participate in the pathogenesis of vascular diseases has now gained widespread recognition

173 arcts (CMIs), a novel MRI marker of cerebral vascular disease, have not been studied, to date, in rel

174 iovascular Events [e.g., Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients W

175 be deployed to counteract atheroinflammatory vascular diseases, highlighting the promise of nanomedic

176 n inflammation (eg, in the skin) may improve vascular diseases; however, randomized clinical trials a

177 nited Kingdom, the probability of death from vascular disease in middle-aged men (35-69 years) has de

178 and pay increased attention to prevention of vascular disease in obese individuals with diabetes.

179 ugh the vast majority of patients have known vascular disease in other territories and multiple treat

180 The increased risk for vascular disease in patients with diabetes, in combinati

181 The role of pulmonary vascular disease in pulmonary exacerbations is unknown.

182 onas oryzae pv. oryzae (Xoo), which causes a vascular disease in rice, on rice plants and consequent

183 These findings are consistent with a role of vascular disease in the development of Alzheimer disease

184 n applied in combination to evaluate retinal vascular disease in the operating suite.

185 largely comparable between groups with more vascular disease in the RF group (8.2% versus 2.6% for C

186 osis and management of cardiac and pulmonary vascular disease in this population are provided to offe

187 rapeutic approach to prevent atherosclerotic vascular disease in this setting.

188 ngs implicate plasma PK as a risk factor for vascular disease in type 1 diabetes.

189 r complications of diabetes has been useful, vascular diseases in diabetes may be more interrelated t

190 rged as a significant contributor to retinal-vascular diseases in the previous 2 decades.

191 inflammation, there is a wide range of other vascular diseases in which macrophages and inflammation

192 12 cardiac, cerebrovascular, and peripheral vascular diseases in women and men at different ages.

193 te the PHACTR1 locus (6p24) in risk for five vascular diseases, including coronary artery disease, mi

194 This suggests that pulmonary vascular disease is a key mechanism underlying Fontan fa

195 Peripheral vascular disease is a strong predictor of mortality in K

196 ses, and their formation in animal models of vascular disease is associated with increased thromboinf

197 standing of the pathophysiology of pulmonary vascular disease is incomplete, since information about

198 Atherothrombotic vascular disease is often triggered by a distinct type o

199 ene (BMPR2), but how these promote pulmonary vascular disease is unclear.

200 ement of Rho proteins in the pathogenesis of vascular diseases is well studied, little is known about

201 soconstrictive and inflammatory signaling in vascular disease, is overexpressed aberrantly in some br

202 vessel function, and predisposes to systemic vascular diseases, its effects on the pulmonary circulat

203 e cells upon culture conditions, yielding a "vascular disease-like" phenotype.

204 ad previously diagnosed diabetes), and other vascular disease (mainly stroke).

205 agents when treating those at high risk for vascular disease may be important.

206 This finding indicates that vascular disease may be more important in the aetiology

207 The etiology of some oxidative vascular diseases may very well be explained by the dysf

208 In patients with various manifestations of vascular disease, median 10-year risk of a recurrent maj

209 In the search for markers and modulators of vascular disease, microRNAs (miRNAs) have emerged as pot

210 g human cardiogenesis, and as a platform for vascular disease modelling and drug screening.

211 ere are many different causes of cardiac and vascular disease, most causes share an important patholo

212 shock, renal disease, history of peripheral vascular disease, multivessel disease, widowhood, and la

213 art disease, cerebrovascular, and peripheral vascular disease), musculoskeletal disorders, and asthma

214 ds ratio, 1.34; 95% CI, 1.24-1.45), collagen vascular disease (odds ratio, 1.30; 95% CI, 1.15-1.46),

215 an estimated 10-year risk of atherosclerotic vascular disease of >/=7.5%, which is lower than the thr

216 65-75, as well as double impact of age >75, vascular disease) of 4.2+/-1.5, and a mean HASBLED (hype

217 now More Than We Can Tell About Diabetes and Vascular Disease," on Sunday, 12 June 2016.Diabetes is a

218 nd III obesity were 2.2 (95% CI 1.9-2.6) for vascular disease only (coronary heart disease or stroke)

219 DNA damage can thus directly cause vascular disease, opening up new possibilities for both

220 hypertension, and the majority had no known vascular disease or heart failure.

221 )] and greater odds of large-vessel cerebral vascular disease or history of cardiovascular disease bu

222 CL: 1.08 to 1.34), and underlying peripheral vascular disease (OR: 4.86; 95% CL: 1.66 to 14.22).

223 r/panuveitis, systemic vasculopathy, retinal vascular disease, or active inflammation.

224 y event, a cerebrovascular event, peripheral vascular disease, or heart failure), death, myocardial i

225 ic obstructive pulmonary disease, peripheral vascular disease, or renal disease.

226 (with inflammatory bowel disease, mesenteric vascular diseases, or other conditions).

227 creasing 6MWD (P </= 0.009) except pulmonary vascular disease (P = 0.74); however, the low volume in

228 chronic disease, including severe peripheral vascular disease, patchy cardiac fibrosis, and hepatic s

229 of cellular responses that may contribute to vascular disease pathogenesis.

230 ven model for the interrelationships between vascular disease pathology, amyloid pathology, and longi

231 ng continues to advance our understanding of vascular disease pathophysiology.

232 dy mass index and higher rates of peripheral vascular disease (per each 1-standard deviation increase

233 roadened the options for treating peripheral vascular disease percutaneously.

234 om the ADVANCE study (Action in Diabetes and Vascular Disease: Peterax and Diamicron MR Controlled Ev

235 The underlying pulmonary hypertensive vascular disease (PHVD) is characterized by inflammation

236 Among 5529 individuals without vascular disease, pravastatin reduced the risk of corona

237 event, peak troponin T level, and peripheral vascular disease predict mortality within 30 days of PCI

238 om the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled E

239 , history of diabetes mellitus or peripheral vascular disease, primary renal disease classification,

240 schemic attack or thromboembolism [doubled], vascular disease [prior myocardial infarction, periphera

241 t ischemic attack/thromboembolism [doubled], vascular disease [prior myocardial infarction, periphera

242 Vascular disease progression is associated with marked c

243 hat inhibiting IL-1beta may favorably affect vascular disease progression.

244 ging techniques for analysis of intracranial vascular disease provide limited information since they

245 medical practitioners in treating Peripheral Vascular Disease (PVD) and Coronary Artery Disease (CAD)

246 The association between peripheral vascular disease (PVD) and survival among kidney transpl

247 crease in risk for development of peripheral vascular disease (PVD) in afflicted persons.

248 angina, heart attack, stroke, and peripheral vascular disease (PVD) were determined.

249 In systemic vascular diseases, reduced miR-204 expression promotes v

250 Patients with atherosclerotic vascular disease remain at high risk for cardiovascular

251 nges within individual VSMCs, which underlie vascular disease, remain unresolved.

252 nced by arterial stiffness in the absence of vascular disease remains uncertain.

253 in trials in which all enrolled patients had vascular disease, renal disease, or diabetes.

254 on average, 1.1 million women without prior vascular disease reported their frequency of physical ac

255 osis (SSc) is a multisystem inflammatory and vascular disease resulting in extensive tissue fibrosis.

256 Statin therapy has been shown to reduce vascular disease risk during each year it continues to b

257 stment for socioeconomic status, traditional vascular disease risk factors, race/ethnicity, body mass

258 s cohort, the relation of age at menarche to vascular disease risk was U shaped, with both early and

259 Renal vascular disease (RVD) induces ischemic injury character

260 bsolute benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patie

261 tion characterized by severe and early-onset vascular disease similar to FMD and variable penetrance

262 Patients with Cpc-PH develop pulmonary vascular disease similar to patients with PAH, despite y

263 terstitial fibrosis and tubular atrophy, and vascular disease; specimens with a score of 0 or 1 (scal

264 des insights into the influence of pulmonary vascular disease, spontaneous respiration and dynamic st

265 ata collection for this analysis on systemic vascular diseases started on December 2, 2010, and ended

266 te a possible link between hyperglycemia and vascular disease states associated with smooth muscle co

267 e of these vascular wall progenitor cells in vascular disease states, adding weight to the notion tha

268 ravastatin in Elderly Individuals at Risk of Vascular Disease Study), then pooled by using random eff

269 ave very different susceptibility to certain vascular diseases such as atherosclerosis and vascular c

270 nt susceptibilities of arteries and veins to vascular diseases such as atherosclerosis and vascular c

271 livery of RNAi based therapies for pulmonary vascular diseases such as pulmonary arterial hypertensio

272 herosclerosis from large-artery inflammatory vascular disease, such as Takayasu arteritis, chemothera

273 proximity of these loci to genes involved in vascular disease suggests potential biological mechanism

274 6 years younger, with more severe pulmonary vascular disease than patients with Ipc-PH, despite simi

275 represents an intrinsic mechanism for human vascular disease that manifests clinical complications i

276 c aneurysm and dissections (AADs) are common vascular diseases that carry a high mortality rate.

277 SSPiM is a novel imaging feature of retinal vascular diseases that was not appreciated prior to the

278 Although diabetes is also a risk factor for vascular disease, the few studies of diabetes and ALS ha

279 In 2 young children with retinal vascular disease, the MIOCTA images showed more detailed

280 Among patients with clinically manifest vascular disease, the risk of recurrent vascular events

281 he global impact of macrophage activation in vascular disease, the underlying mechanisms remain obscu

282 nerally been associated with reduced risk of vascular disease, there is limited evidence about the ef

283 Among patients with vascular disease, there is very substantial variation in

284 cardiometabolic risk factors and subtypes of vascular disease, thereby suggesting differing roles in

285 In vascular disease, this process is activated inappropriat

286 However, excessive levels of ROS promote vascular disease through direct and irreversible oxidati

287 oke risk ranged from 1.96%/year for men with vascular disease to 3.50%/year for those 65 to 74 years

288 Vascular disease, tuberculosis, malaria and other infect

289 erized tomography among PLWHIV without known vascular disease were described.

290 lyses, 5529 participants without evidence of vascular disease were included, stratified by LDL-C leve

291 in these patients, compared with those with vascular disease, which is a missed opportunity for prev

292 l stiffening, endothelial contractility, and vascular disease, which is controlled by Rho-driven acto

293 EX) syndrome may be associated with systemic vascular diseases, which might suggest a broader health

294 involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastat

295 Among patients with atherosclerotic vascular disease who were receiving intensive statin the

296 n with optimal treatment, many patients with vascular disease will remain at >20% and even >30% 10-ye

297 metformin, are potentially useful to prevent vascular disease with minimal adverse effects.

298 to suggest progressive reductions in risk of vascular diseases with increasing frequency of activity.

299 proliferating VSMCs might effectively reduce vascular disease without affecting vascular integrity.

300 Atherosclerosis is a leading cause of vascular disease worldwide.